Stryker (NYSE:SYK) Raised to “Buy” at Wall Street Zen

Stryker (NYSE:SYK) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

SYK has been the subject of a number of other reports. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Truist Financial raised their target price on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Wolfe Research set a $375.00 target price on shares of Stryker in a report on Friday, July 31st. Raymond James Financial set a $370.00 price target on shares of Stryker in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. lowered their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Stock Performance

SYK opened at $338.85 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company has a market cap of $129.97 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The stock has a 50-day moving average of $320.11 and a 200-day moving average of $333.92. Stryker has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts forecast that Stryker will post 15.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of Stryker

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the fourth quarter valued at $26,000. Sankala Group LLC bought a new position in Stryker during the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter valued at about $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker in the fourth quarter valued at about $27,000. Finally, DJE Kapital AG bought a new stake in Stryker during the fourth quarter worth about $28,000. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.